BioNxt获得了一种新的亚语言肿瘤药物的专有权利,并制定了发展和欧洲商业化计划。 BioNxt acquires exclusive rights to a new sublingual oncology drug, with plans for development and European commercialization.

BioNxt Solutions Inc.与一家欧洲化疗公司签署了一份信函协议,为用于肿瘤学和免疫抑制剂治疗的新型亚语文药物配方获得专有知识产权。 BioNxt Solutions Inc. has signed a letter agreement with a European chemotherapy company to acquire exclusive intellectual property rights for a novel sublingual drug formulation intended for oncology and immunosuppressant treatments. 根据该协定,BioNxt将牵头发展,包括专利申请和临床研究,该伙伴在第三方许可证费方面获得20%的特许使用费,最高限额为5 000万美元。 Under the agreement, BioNxt will lead development, including patent filings and clinical studies, with the partner receiving a 20% royalty on third-party license fees, capped at $50 million. 这些公司的目标是在60天内最后敲定一项最终协议。 The companies aim to finalize a definitive agreement within 60 days. 支持BioNxt现有的多种硬化症亚语言薄膜计划, 并与预计2025年全球免疫抑制市场61.05亿美元相符。 The move supports BioNxt’s existing sublingual thin-film program for multiple sclerosis and aligns with the projected $61.05 billion global immunosuppressant market in 2025. 该公司计划在年底前提交临时专利申请,并继续推进北美和欧洲的药物供应平台,以欧洲市场为重点实现商业化。 The company plans to file provisional patents by year-end and continues advancing drug delivery platforms in North America and Europe, with commercialization focused on European markets.